Saint Luke's Mid America Heart Institute

Fellowship application season is upon us! @UMKC and Saint Luke's @MidAmericaHeart offers: ✴️ 3 yr CV fellowship ✴️ 4 yr T32 clinical/research track ✴️ Advanced HF ✴️ EP ✴️ Interventional ✴️ Structural ✴️ CV Imaging ✴️ Prevention Apply today! saintlukeskc.org/cardiovascular…

Great opportunity!

Come join us! @AndrewJSauer @jspertus @jamesokeefemd @akcmahi @chetanhuded @MichaelNassifMD @michaelleemain @erikahuttce @TimBateman6 @DeZorzi_MD @JAG24851 @DanyJacob87 @Lehenbauer_K @heartrct saintlukes.wd1.myworkdayjobs.com/saintlukesheal…

Apply for Structural Intervention fellowship here! Excellent opportunity to train at a high volume program.

The Cardiovascular Structural Intervention Fellowship through @UMKCMedSchool and @MidAmericaheart accepts one candidate per academic year. Fellows benefit from getting hands-on training from renowned specialists. Learn more and request an application now: heyor.ca/A8M1n1

Congratulations to Rich Liekweg, BJC Health System CEO, who announced his plans to retire on October 1, 2025. BJC is pleased to announce that Nick Barto, current BJC Health System President, will succeed Rich as President and CEO of BJC Health System: heyor.ca/j1yUMR

Star fellow @mirzakhan_ presenting data on geographic patterns of prescriptions for amyloid medications from EPIC Cosmos at #ACC25 @MidAmericaHeart

Understanding patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM) is vital for managing treatment effectively. We recently validated the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) in this population. Here’s why it matters: A quick🧵 doi.org/10.1016/j.card…

At #ESCHF2025 🇷🇸 @MidAmericaHeart fellow Dr Omar Cantu-Martinez presents #CAREHKinHF real-world registry: >2,300 HF pts w/ hyperK risk with 9% on clinician selected patiromer. Reduced severe HK and trend toward more optimal GDMT. Take-home: early K⁺ control keeps GDMT on & protects heart + kidneys

Grateful for the opportunity to work with @Amgen in collaboration with @cardiometalli @MidAmericaHeart as part of the LATTICE Consortium to address implementation of cardiometabolic therapies and stepping into the gaps.

Special focus issue in @JACCJournals this week on Cardiac Amyloidosis. Many important articles! Sharing my editorial with Joban Vaishnav from @JohnsHopkins sciencedirect.com/journal/journa…

One of the defining aspects of our fellowship are our accomplished alumni. As a part of our fellowship research day, Dr. Chhatriwalla honored us with a noon conference on advancements in ViV TAVR and bioprosthetic valve fracture! @akcmahi @venumenon10

Art Still, a former @Chiefs defensive end, has dedicated himself to increasing awareness for ATTR amyloidosis ever since his diagnosis in 2023. @TODAYshow spoke with Dr. Brett Sperry, a @MidAmericaHeart cardiologist, to discuss the rare genetic condition: heyor.ca/FH3BGP

Outside of her work as an oncologist, Dr. Juliet Appiah helps cancer patients in her home country of Ghana. Dr. Appiah spoke with @KSHB41 about her passion for giving back to her home country and raising awareness for all types of cancer. Watch now: heyor.ca/7WUskq

Here are some reasons why you should train with us in Cardiovascular Disease at the University of Missouri-Kansas City School of Medicine program @MidAmericaHeart @saintlukeskc!

Proof I made it to @escardio Let’s go! Check out @JACCJournals publications our team is releasing soon during London sessions. jacc.org/events/confere… @MkosiborodMD @jspertus @MidAmericaHeart @saintlukeskc

Semaglutide and obesity related HFpEF Patients with atrial fibrillation and obesity HFpEF are generally more burdened/congested at baseline and also may benefit more from GLP1 in health status and walking distance. @MkosiborodMD @MidAmericaHeart jacc.org/doi/10.1016/j.…

Inflammation reduction by semaglutide as measured by CRP tracks with magnitude of NTproBNP reduction.

Semaglutide and obesity HFpEF Echo markers Improved LA volume reduction and markers of diastolic function with GLP1 compared to placebo. @mvaduganathan @BiykemB @MkosiborodMD

CV outcomes from FLOW trial. Semaglutide vs placebo focused on patients with HF within larger population of T2DM and CKD.

Pooled analysis of patients with HFpEF in STEP-HFpEF, SELECT, and FLOW @MkosiborodMD @MidAmericaHeart @saintlukeskc @mvaduganathan